Eccleston Law: For Investors. For Advisors
About
Who We Are
Testimonials
Disclaimers
Attorneys
For Advisors
Broker Transition
Transition Contract Review
Employment Matters
State Registration Problems & Discipline
FINRA Matters
Promissory Note Matters
Team/Parnership Disputes
CFP Board Matters
FINRA Enforcement Matters
State Registration Problems & Discipline
Transition Contract Review
Broker Litigation & Arbitration
Employment Matters
Regulatory Matters
Strategic Consulting
Whistleblower Law
Promissory Note Matters
Compliance Protection
Lawyer Referral Network
Expungement of CRD/BrokerCheck Disclosures
For Investors
Securities Fraud
Breach of Fiduciary Duty
Retirement Planning Negligence
Unauthorized Trading
Lawyer Referral Network
FAQs
News & Articles
News
Articles
Financial Counsel Blog
Videos
Newsletter Signup
Contact
Site Menu
About
Who We Are
Testimonials
Disclaimers
Attorneys
For Advisors
For Advisors: Overview
Broker Transition
Broker Transition Overview
Transition Contract Review
Employment Matters
State Registration Problems & Discipline
FINRA Matters
Promissory Note Matters
Team/Parnership Disputes
CFP Board Matters
FINRA Enforcement Matters
State Registration Problems & Discipline
Transition Contract Review
Broker Litigation & Arbitration
Employment Matters
Regulatory Matters
Strategic Consulting
Whistleblower Law
Promissory Note Matters
Compliance Protection
Lawyer Referral Network
Expungement of CRD/BrokerCheck Disclosures
For Investors
For Investors: Overview
Securities Fraud
Breach of Fiduciary Duty
Retirement Planning Negligence
Unauthorized Trading
Lawyer Referral Network
FAQs
News & Articles
News
Articles
Financial Counsel Blog
Videos
Newsletter Signup
Contact

Securities Regulators Focus On Complex Products To Better Protect Investors

Posted on January 31st, 2012 at 9:40 AM

FINRA (the Financial Industry Regulatory Authority) has issued a warning to financial services firms that they need to heighten their supervision of and compliance procedures associated with complex products.  Complex products include any security or investment strategy with “novel, complicated or intricate derivative-like features.”  The basic rationale for heightened supervision is the fact that FINRA is concerned that retail investors may not understand the characteristics of the product or appreciate its risks. 

 

            As background, Regulatory Notice 12-03 is not the first notification that FINRA has provided to financial services firms. As early as 2003 FINRA sounded the alarm.  In Notice to Members 03-07, FINRA reminded members of their obligations with respect to selling hedge funds, and in Notice to Members 03-71, they did the same with respect to selling “non-conventional” investments.  Similarly in 2005, Notice to Members 05-26 recommended best practices with respect to reviewing new products.  Thereafter, the securities regulator issued numerous notices related to equity-indexed annuities, structured products, leveraged and inverse exchange-traded funds, principal protected notes, reverse convertibles, commodity futures-linked securities and Regulation D offerings. 

 

The Securities and Exchange Commission (SEC) likewise has expressed concern about complex products, has devoted more resources to the issues presented by complex products, and, in recent years, has brought a number of enforcement cases. 

 

            Let’s examine the key points contained in Regulatory Notice 12-03, focusing first on what constitutes complexity, broadly speaking, and, second, what constitutes effective, heightened supervision. 

 

First, what constitutes complexity?  FINRA answers that question simply by stating that, “Any product with multiple features that affect its investment returns differently under various scenarios is potentially complex.”  FINRA includes the following as some examples of complex products:

 

  • Asset-backed securities.
  • Unlisted REITs (real estate investment trusts).
  • Products that include an embedded derivative component.
  • Products with contingencies in gains or losses. 
  • Structured notes.
  • Exchange-traded products and especially leveraged or inverse exchange-traded funds (ETFs).
  • Products with principal protection that is conditional or partial, or that can be withdrawn.

 

Second, what constitutes heightened supervision?  Preliminarily, firms must satisfy two levels of suitability.  As with any investment, the first obligation is to determine that the complex product is suitable for at least some investors (known as “reasonable basis suitability”); the second is to determine that the complex product is suitable for each particular investor to whom the firm recommends the investment (known as “customer specific suitability”).

 

To satisfy each level of suitability, firms must conduct adequate due diligence, so that the firm at least understands “the potential risks and rewards associated with the recommended security or strategy.”  Regulatory Notice 12-03 requires that a complex product be “thoroughly vetted”, through firms asking questions such as:

 

  • For whom is the product intended, and to whom should the product not be offered?
  • What is the product’s investment objective, is that objective reasonable in light of the product’s characteristics, and can less complex products achieve the objectives of the product?
  • What assumptions underlie the product, and how sound are they?
  • How is the product expected to perform in a wide variety of market or economic scenarios, and under what scenarios would principal protection, enhanced yield or other presumed benefits not occur?
  • What are the risks for investors, and if the product was designed mainly to generate yield, does the yield justify the risks to the principal?
  • How liquid is the product, and is there an active secondary market for the product?

 

Moreover, FINRA imposes additional requirements by way of a post-approval review.  That is, firms are required to “include a process to periodically reassess complex products a firm offers to determine whether their performance and risk profile remain consistent with the manner in which the firm is selling them.”  Likewise, firms should develop procedures to “monitor how the products performed after the firm approved them”, recognizing that “[e]very product presents risks that may cause the product to perform differently than anticipated, particularly when market conditions have changed.”

 

Finally, the regulatory notice encourages firms to adopt heightened customer account approval procedures.  Specifically in recommending complex products, FINRA encourages firms to “adopt the approach mandated for options trading accounts, which requires that a registered representative have a reasonable basis for believing, at the time of making the recommendation, that the customer has such knowledge and experience in financial matters that he may reasonably be expected to be capable of evaluating the risks of the recommended transaction, and is financially able to bear the risks of the recommended position in the complex product.”  In addition, FINRA observes that some firms have imposed specific limitations, such as investment concentration limitations, or “specialized investor qualification agreements that may explain the products features and risk in plain English” with a customer attestation.  FINRA reminds firms, however, that “the agreement cannot mitigate the responsibility of the firm and the registered representative to conduct a thorough, customer-specific suitability analysis.”

 

In conclusion, Regulatory Notice 12-03 is a game-changer!  Investors, who have suffered losses, due to unsuitable recommendations and inadequate risk disclosures related to complex products, now can rejoice that FINRA has reminded firms of their sales practice obligations.

Tags:

Share

Return to Archive

Latest Articles
Carve-Out Provision Plays A Crucial Role in Morgan Stanley Advisor Transition Battle
February 25th, 2021 at 3:18 PM
SEC Sues Morningstar Over Undisclosed Changes to Bond Ratings
February 24th, 2021 at 3:37 PM
Read More »
Latest News
CFP Board is the New Sheriff and it Is Not Your Friend
October 24th, 2020 at 10:04 AM
Defending Against a Customer Complaint First Requires Selecting Correct Legal Counsel
October 15th, 2020 at 10:02 AM
Read More »
Share

Request a Free Consultation

Attorneys are standing by during regular business hours. Call us now for immediate service, or complete the form below and we will contact you as soon as possible.

Your E-mail Address:
 
Chicago
55 West Monroe St.
Suite 610
Chicago, Illinois 60603
(312) 332-0000
(312) 332-0003
New York City
One Liberty Plaza
165 Broadway, 23rd Floor
New York, New York 10006
(312) 332-0000
(312) 332-0003
Boca Raton
2255 Glades Road
Suite 324A
Boca Raton, Florida 33431
(312) 332-0000
(312) 332-0003
2021 © Eccleston Law, LLC.
All Rights Reserved.
The law is continuously changing. Please do not rely on information found on this site without consulting a lawyer to determine if any recent changes in the law may have an impact.